68 Ga PSMA PET/MRI for Hepatocellular Carcinoma

• Status: Active, not recruiting
• Trial end date: 2022-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a pilot study to investigate the evaluate to use of a drug/radiopharmaceutical called Gallium-68 PSMA-11 (68Ga-PSMA-11) for use in PET/MRI evaluation of hepatocellular carcinoma

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ajit H. Goenka, MD
• Treatments: Gallium 68 PSMA-11

Criteria

Inclusion Criteria:

• Patients at risk for HCC with either an imaging diagnosis of HCC by ceCT or ceMRI (LI-RADS 5) confirmed by a board-certified abdominal radiologist or biopsy-proven HCC confirmed by a hepatobiliary pathologist

• No prior treatment for HCC

• Subjects who are expected to undergo surgical resection of the hepatic lesion(s) and/or liver transplant

• Male or female with age greater than 18 years, with the capacity to give informed consent and willingness to provide a written consent.

Exclusion Criteria:

• Subjects requiring emergent surgery for a ruptured/bleeding HCC

• Bilirubin > 3.0 mg/dL, which is a contraindication for Gadoxetate, the MRI contrast agent

• Pregnant and/or breast-feeding subjects. A negative pregnancy test within 48 hours of the PET scan.

• Subjects with higher than the weight/size limitations of PET/MRI scanner.

• Subjects with contraindication to MRI including: Subjects who have a heart pacemaker, subjects who have a metallic foreign body (metal sliver) in their eye, or who have an aneurysm clip in their brain, subjects who have implanted devices with magnets, subjects who have other implanted electronic devices, subjects who have deep brain stimulator, subjects who have vagal nerve stimulator, subjects with cochlear (ear) or auditory implants

• Subjects with history of allergic response to radiocontrast media

• Subjects with known history of claustrophobia.